Hepatitis C virus status has an impact on hemodialysis patients with end-stage renal illness who have low Hemoglobin and Hematocrit levels. The most frequent haematological anomaly in chronic renal failure is anaemia. Patients with renal failure frequently have an iron deficiency, and treatment with erythropoietin (EPO) increases this demand. It is unclear whether higher iron storage influences to hepatitis C virus (HCV) infection or whether HCV infection helps iron accumulation, making the Hepatitis C virus infections are chronic in over 170 million people globally (HCV). HCV infection is widespread in hemodialysis (HD) facilities around the world, mostly in the Mediterranean and developing nations of the Middle and Far East, and is persistently more common among patients receiving dialysis than in the general population. In contemporary hospital dialysis facilities, nosocomial transmission of HCV infection has been documented to be a significant pathway, particularly during outbreaks of HCV. [1–4]. The most effective way to treat renal anaemia in the past was blood transfusions, its no longer required due to the use of erythropoietin (EPO).Renal anaemia must be treated with iron replacement since erythropoietin therapy increases the need for iron.

.